guidelines:
  1: Global_Initiative_for_Obstructive_Lung_Disease_GOLD_Criteria_for_COPD_guideline.v1
test_cases:
- id: GOLD B, Grade 4,10.6%, LABA or LAMA
  input:
    1:
      gt0003|Symptom burden: local::at0006|Higher (mMRC ≥2 or CAT Score ≥10)|
      gt0004|Exacerbation history: local::at0008|0 exacerbations|
      gt0005|FEV₁ % of predicted: local::at0016|<30|
  expected_output:
    1:
      gt0007|GOLD group: local::at0019|GOLD B|
      gt0008|Grade of airflow obstruction: local::at0026|Grade 4 airflow obstruction|
      gt0020|Pharmacologic treatment recommendation: local::at0009|Long-acting bronchodilator (LABA) or long-acting methacholine antagonist (LAMA)|
      gt0019|3-year mortality: local::at0005|10.6%|

- id: GOLD D, Grade 4, 20.1%, LAMA and LABA
  input:
    1:
      gt0003|Symptom burden: local::at0006|Higher (mMRC ≥2 or CAT Score ≥10)|
      gt0004|Exacerbation history: local::at0012|≥2 exacerbations|
      gt0005|FEV₁ % of predicted: local::at0016|<30|
  expected_output:
    1:
      gt0007|GOLD group: local::at0021|GOLD D|
      gt0008|Grade of airflow obstruction: local::at0026|Grade 4 airflow obstruction|
      gt0020|Pharmacologic treatment recommendation: local::at0012|LAMA and LABA, plus inhaled corticosteroid (ICS) if frequent exacerbations|
      gt0019|3-year mortality: local::at0007|20.1%|

- id: GOLD C, Grade 3 , LAMA, 8.2%
  input:
    1:
      gt0003|Symptom burden: local::at0005|Lower (mMRC <2 or CAT Score <10)|
      gt0004|Exacerbation history: local::at0012|≥2 exacerbations|
      gt0005|FEV₁ % of predicted: local::at0015|30–49|
  expected_output:
    1:
      gt0007|GOLD group: local::at0020|GOLD C|
      gt0008|Grade of airflow obstruction: local::at0025|Grade 3 airflow obstruction|
      gt0020|Pharmacologic treatment recommendation: local::at0011|LAMA (or LAMA + LABA, or LABA + ICS (inhaled corticosteroids) if frequent exacerbations)|
      gt0019|3-year mortality: local::at0006|8.2%|

- id: GOLD A, Grade 1, Bronchodilator, 3.8%
  input:
    1:
      gt0003|Symptom burden: local::at0005|Lower (mMRC <2 or CAT Score <10)|
      gt0004|Exacerbation history: local::at0008|0 exacerbations|
      gt0005|FEV₁ % of predicted: local::at0013|≥80|
  expected_output:
    1:
      gt0007|GOLD group: local::at0018|GOLD A|
      gt0008|Grade of airflow obstruction: local::at0023|Grade 1 airflow obstruction|
      gt0020|Pharmacologic treatment recommendation: local::at0008|Bronchodilator (long- or short-acting) |
      gt0019|3-year mortality: local::at0004|3.8%|

- id: GOLD A, Grade 2 , Bronchodilator, 3.8%
  input:
    1:
      gt0003|Symptom burden: local::at0005|Lower (mMRC <2 or CAT Score <10)|
      gt0004|Exacerbation history: local::at0010|1 exacerbation without hospital admission|
      gt0005|FEV₁ % of predicted: local::at0014|50–79|
  expected_output:
    1:
      gt0007|GOLD group: local::at0018|GOLD A|
      gt0008|Grade of airflow obstruction: local::at0024|Grade 2 airflow obstruction|
      gt0020|Pharmacologic treatment recommendation: local::at0008|Bronchodilator (long- or short-acting) |
      gt0019|3-year mortality: local::at0004|3.8%|







